Top

Annals of Nuclear Medicine

Published in:

01-02-2019 | Original Article

Characteristics of iodine-123 IQ-SPECT/CT imaging compared with conventional SPECT/CT

Authors: Takayuki Shibutani, Masahisa Onoguchi, Hiroto Yoneyama, Takahiro Konishi, Shinro Matsuo, Kenichi Nakajima

Published in: Annals of Nuclear Medicine | Issue 2/2019

Abstract

Objectives

Although the utility of IQ-SPECT imaging using ^99mTc and ²⁰¹Tl myocardial perfusion SPECT has been reported, ¹²³I-labeled myocardial SPECT has not been fully evaluated. We determined the characteristics and utility of ¹²³I IQ-SPECT imaging compared with conventional SPECT (C-SPECT).

Methods

Two myocardial phantom patterns were used to simulate normal myocardium and myocardial infarction. SPECT acquisition was performed using a hybrid dual-head SPECT/CT system equipped with a SMARTZOOM collimator for IQ-SPECT or a low-medium energy general purpose collimator for C-SPECT. Projection data were reconstructed using ordered subset expectation maximization with depth-dependent 3-dimensional resolution recovery for C-SPECT and ordered subset conjugate gradient minimizer method for IQ-SPECT. Three types of myocardial image were created; namely, no correction (NC), with attenuation correction (AC), and with both attenuation and scatter corrections (ACSC). Five observers visually scored the homogeneity of normal myocardium and defect severity of the myocardium with inferior defects by a five-point scale: homogeneity scores (5 = homogeneous to 1 = inhomogeneous) and defect scores (5 = excellent to 1 = poor). We also created a 17-segment polar map and quantitatively assessed segmental %uptake using a myocardial phantom with normal findings and defects.

Results

The average visual homogeneity scores of the IQ-SPECT with NC and ACSC were significantly higher than that of C-SPECT, whereas the average visual defect scores of IQ-SPECT with AC and ACSC were significantly lower. The %uptake of all segments for IQ-SPECT with NC was significantly higher than that of C-SPECT. Furthermore, the subtraction of %uptake for C-SPECT and IQ-SPECT was the largest in inferior wall, which was approximately 10.1%, 14.7% and 14.4% for NC, AC and ACSC, respectively. The median % uptake values of the inferior wall with defect areas for C-SPECT and IQ-SPECT were 46.9% and 50.7% with NC, 59.8% and 69.2% with AC, and 54.7% and 66.5% with ACSC, respectively.

Conclusion

¹²³I IQ-SPECT imaging significantly improved the attenuation artifact compared with C-SPECT imaging. Although the defect detectability of IQ-SPECT was inferior to that of C-SPECT, ¹²³I IQ-SPECT images with NC and ACSC met the criteria for defect detectability. Use of ¹²³I IQ-SPECT is suitable for routine examinations.

Matsuo S, Nakajima K, Yamashina S, Sakata K, Momose M, Hashimoto J, et al. Characterization of Japanese standards for myocardial sympathetic and metabolic imaging in comparison with perfusion imaging. Ann Nucl Med. 2009;23:517–22.CrossRefPubMed

Nakajima K, Nakata T, Matsuo S, Jacobson AF. Creation of mortality risk charts using 123I meta-iodobenzylguanidine heart-to-mediastinum ratio in patients with heart failure: 2- and 5-year risk models. Eur Heart J Cardiovasc Imaging. 2016;17:1138–45.CrossRefPubMed

Matsuo S, Nakajima K, Nakata T. Prognostic value of cardiac sympathetic nerve imaging using long-term follow-up data—ischemic vs. non-ischemic heart failure etiology. Circ J. 2016;80:435–41.CrossRefPubMed

Matsuo S, Nakajima K. Assessment of cardiac sympathetic nerve function using 123i-meta-iodobenzylguanidine scintigraphy: technical aspects and standardization. Ann Nucl Cardiol. 2015;1:27–34.CrossRef

Nakajima K, Nakata T, Yamada T, Yamashina S, Momose M, Kasama S, et al. A prediction model for 5-year cardiac mortality in patients with chronic heart failure using ¹²³I-metaiodobenzylguanidine imaging. Eur J Nucl Med Mol Imaging. 2014;41:1673–82.CrossRefPubMedPubMedCentral

Somsen GA, van Vlies B, de Milliano PA, Borm JJ, van Royen EA, Endert E, et al. Increased myocardial [123I]-metaiodobenzylguanidine uptake after enalapril treatment in patients with chronic heart failure. Heart. 1996;76:218–22.CrossRefPubMedPubMedCentral

Kinbara T, Hayano T, Otani N, Furutani Y, Tanaka S. Iodine-123 metaiodobenzylguanidine imaging can predict future cardiac events in Japanese patients with Parkinson’s disease. Ann Nucl Med. 2013;27:123–31.CrossRefPubMed

Taki J, Yoshita M, Yamada M, Tonami N. Significance of ¹²³I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson’s disease and related disorders: it can be a specific marker for Lewy body disease. Ann Nucl Med. 2004;18:453–61.CrossRefPubMed

Odagiri H, Baba T, Nishio Y, Iizuka O, Matsuda M, Inoue K, et al. On the utility of MIBG SPECT/CT in evaluating cardiac sympathetic dysfunction in lewy body diseases. PLoS One. 2016;11:e0152746.CrossRefPubMedPubMedCentral

10.

Yoshita M, Arai H, Arai H, Arai T, Asada T, Fujishiro H, et al. Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: a multicenter study. PLoS One. 2015;10:e0120540.CrossRefPubMedPubMedCentral

11.

Sakamoto F, Shiraishi S, Yoshida M, Tomiguchi S, Hirai T, Namimoto T, et al. Diagnosis of dementia with Lewy bodies: diagnostic performance of combined ¹²³I-IMP brain perfusion SPECT and ¹²³I-MIBG myocardial scintigraphy. Ann Nucl Med. 2014;28:203–11.CrossRefPubMed

12.

Nakajima K, Yoshita M, Matsuo S, Taki J, Kinuya S. Iodine-123-MIBG sympathetic imaging in Lewy-body diseases and related movement disorders. Q J Nucl Med Mol Imaging. 2008;52:378–87.PubMed

13.

Inui Y, Toyama H, Manabe Y, Sato T, Sarai M, Kosaka K, et al. Evaluation of probable or possible dementia with lewy bodies using 123I-IMP brain perfusion SPECT, ¹²³I-MIBG, and ^99mTc-MIBI myocardial SPECT. J Nucl Med. 2007;48:1641–50.CrossRefPubMed

14.

Takeishi Y, Fujiwara S, Atsumi H, Takahashi K, Sukekawa H, Tomoike H. Iodine-123-BMIPP imaging in unstable angina: a guide for interventional strategy. J Nucl Med. 1997;38:1407–11.PubMed

15.

Nakajima K, Shimizu K, Taki J, Uetani Y, Konishi S, Tonami N, et al. Utility of iodine-123-BMIPP in the diagnosis and follow-up of vasospastic angina. J Nucl Med. 1995;36:1934–40.PubMed

16.

Matsuo S, Nakajima K, Kinuya S, Yamagishi M. Diagnostic utility of ¹²³I-BMIPP imaging in patients with Takotsubo cardiomyopathy. J Cardiol. 2014;64:49–56.CrossRefPubMed

17.

Cooper JA, Neumann PH, McCandless BK. Effect of patient motion on tomographic myocardial perfusion imaging. J Nucl Med. 1992;33:1566–71.PubMed

18.

Botvinick EH, Zhu YY, O’Connell WJ, Dae MW. A quantitative assessment of patient motion and its effect on myocardial perfusion SPECT images. J Nucl Med. 1993;34:303–10.PubMed

19.

Tanaka H, Chikamori T, Hida S, Uchida K, Igarashi Y, Yokoyama T, et al. Comparison of myocardial perfusion imaging between the new high-speed gamma camera and the standard Anger camera. Circ J. 2013;77:1009–17.CrossRefPubMed

20.

De Lorenzo A, Fonseca LM, Landesmann MC, Lima RS. Comparison between short-acquisition myocardial perfusion SPECT reconstructed with a new algorithm and conventional acquisition with filtered back projection processing. Nucl Med Commun. 2010;31:552–7.PubMed

21.

Caobelli F, Thackeray JT, Soffientini A, Bengel FM, Pizzocaro C, Guerra UP. Feasibility of one-eighth time gated myocardial perfusion SPECT functional imaging using IQ-SPECT. Eur J Nucl Med Mol Imaging. 2015;42:1920–8.CrossRefPubMed

22.

Caobelli F, Kaiser SR, Thackeray JT, Bengel FM, Chieregato M, Soffientini A, et al. IQ SPECT allows a significant reduction in administered dose and acquisition time for myocardial perfusion imaging: evidence from a phantom study. J Nucl Med. 2014;55:2064–70.CrossRefPubMed

23.

Zeintl J, Rempel TD, Bhattacharya M, Malmin RE, Vija AH. Performance characteristics of the SMARTZOOM^® collimator. Nuclear science symposium and medical imaging conference (NSS/MIC) IEEE; 2011. p. 2426–9.

24.

Onoguchi M, Konishi T, Shibutani T, Matsuo S, Nakajima K. Technical aspects: image reconstruction. Ann Nucl Cardiol. 2016;2:68–72.CrossRef

25.

Matsuo S, Nakajima K, Onoguchi M, Wakabayash H, Okuda K, Kinuya S. Nuclear myocardial perfusion imaging using thallium-201 with a novel multifocal collimator SPECT/CT: IQ-SPECT versus conventional protocols in normal subjects. Ann Nucl Med. 2015;29:452–9.CrossRefPubMed

26.

Onishi H, Matsutomo N, Kangai Y, Saho T, Amijima H. Differential impact of multi-focus fan beam collimation with L-mode and conventional systems on the accuracy of myocardial perfusion imaging: quantitative evaluation using phantoms. Asia Ocean J Nucl Med Biol. 2013;1:28–34.PubMedPubMedCentral

27.

Havel M, Kolacek M, Kaminek M, Dedek V, Kraft O, Sirucek P. Myocardial perfusion imaging parameters: IQ-SPECT and conventional SPET system comparison. Hell J Nucl Med. 2014;17:200–3.PubMed

28.

Shibutani T, Onoguchi M, Funayama R, Nakajima K, Matsuo S, Yoneyama H, et al. The optimal reconstruction parameters by scatter and attenuation corrections using multi-focus collimator system in thallium-201 myocardial perfusion SPECT study. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2015;71:1103–12.CrossRefPubMed

29.

Okuda K, Nakajima K, Matsuo S, Kondo C, Sarai M, Horiguchi Y, et al. Creation and characterization of normal myocardial perfusion imaging databases using the IQ·SPECT system. J Nucl Cardiol. 2017. https://doi.org/10.1007/s12350-016-0770-2.CrossRefPubMedPubMedCentral

30.

Shibutani T, Onoguchi M, Yoneyama H, Konishi T, Matsuo S, Nakajima K, et al. Characteristics of single- and dual-photopeak energy window acquisitions with thallium-201 IQ-SPECT/CT system. Ann Nucl Med. 2017;31:529–35.CrossRefPubMed

31.

Yoneyama H, Shibutani T, Konishi T, Mizutani A, Hashimoto R, Onoguchi M, et al. Validation of the left ventricular ejection fraction and quantitation of myocardial abnormality with IQ-SPECT system in small-heart patients. J Nucl Med Technol. 2017;45:201–7.CrossRefPubMed

32.

Nakajima K, Okuda K, Momose M, Matsuo S, Kondo C, Sarai M, et al. IQ·SPECT technology and its clinical applications using multicenter normal databases. Ann Nucl Med. 2017;31:649–59.CrossRefPubMedPubMedCentral

33.

Hippeläinen E, Mäkelä T, Kaasalainen T, Kaleva E. Ejection fraction in myocardial perfusion imaging assessed with a dynamic phantom: comparison between IQ-SPECT and LEHR. EJNMMI Phys. 2017;4:20.CrossRefPubMedPubMedCentral

34.

Du Y, Bhattacharya M, Frey EC. Simultaneous Tc-99m/I-123 dual-radionuclide myocardial perfusion/innervation imaging using Siemens IQ-SPECT with SMARTZOOM collimator. Phys Med Biol. 2014;59:2813–28.CrossRefPubMedPubMedCentral

35.

Inoue Y, Shirouzu I, Machida T, Yoshizawa Y, Akita F, Minami M, et al. Collimator choice in cardiac SPECT with I-123-labeled tracers. J Nucl Cardiol. 2004;11:433–9.CrossRefPubMed

36.

Zeintl J, Vija AH, Yahil A, Hornegger J, Kuwert T. Quantitative accuracy of clinical ^99mTc SPECT/CT using ordered-subset expectation maximization with 3-dimensional resolution recovery, attenuation, and scatter correction. J Nucl Med. 2010;51:921–8.CrossRef

37.

Okuda K, Nakajima K, Yamada M, Wakabayashi H, Ichikawa H, Arai H, et al. Optimization of iterative reconstruction parameters with attenuation correction, scatter correction and resolution recovery in myocardial perfusion SPECT/CT. Ann Nucl Med. 2014;28:60–8.CrossRefPubMed

38.

Christian TF, Schwartz RS, Gibbons RJ. Determinants of infarct size in reperfusion therapy for acute myocardial infarction. Circulation. 1992;86:81–90.CrossRefPubMed

39.

Shibutani T, Onoguchi M, Yamada T, Kamida H, Kunishita K, Hayashi Y, et al. Optimization of the filter parameters in (99 m)Tc myocardial perfusion SPECT studies: the formulation of flowchart. Australas Phys Eng Sci Med. 2016;39:571–81.CrossRefPubMed

40.

Tamaki N, Mukai T, Ishii Y, Fujita T, Yamamoto K, Minato K, et al. Comparative study of thallium emission myocardial tomography with 180 degrees and 360 degrees data collection. J Nucl Med. 1982;23:661–6.PubMed

41.

Nakajima K, Okuda K, Kawano M, Matsuo S, Slomka P, Germano G, et al. The importance of population-specific normal database for quantification of myocardial ischemia: comparison between Japanese 360 and 180-degree databases and a US database. J Nucl Cardiol. 2009;16:422–30.CrossRefPubMedPubMedCentral

42.

Dobbeleir AA, Hambÿe AS, Franken PR. Influence of high-energy photons on the spectrum of iodine-123 with low- and medium-energy collimators: consequences for imaging with 123I-labelled compounds in clinical practice. Eur J Nucl Med. 1999;26:655–8.CrossRefPubMed

43.

Nakajima K, Okuda K, Yokoyama K, Yoneyama T, Tsuji S, Oda H, et al. Cross calibration of 123I-meta-iodobenzylguanidine heart-to-mediastinum ratio with D-SPECT planogram and Anger camera. Ann Nucl Med. 2017;31:605–15.CrossRefPubMedPubMedCentral

Title: Characteristics of iodine-123 IQ-SPECT/CT imaging compared with conventional SPECT/CT
Authors: Takayuki Shibutani
Masahisa Onoguchi
Hiroto Yoneyama
Takahiro Konishi
Shinro Matsuo
Kenichi Nakajima
Publication date: 01-02-2019
Publisher: Springer Singapore
Published in: Annals of Nuclear Medicine / Issue 2/2019
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-018-1310-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Characteristics of iodine-123 IQ-SPECT/CT imaging compared with conventional SPECT/CT

Abstract

Objectives

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2019

[99mTc]3PRGD2 for integrin receptor imaging of esophageal cancer: a comparative study with [18F]FDG PET/CT

18F-fluorodeoxyglucose positron emission tomography is correlated with the pathological necrosis and decreased microvessel density in lung adenocarcinomas

Negative remnant 99mTc-pertechnetate uptake predicts excellent response to radioactive iodine therapy in low- to intermediate-risk differentiated thyroid cancer patients who have undergone total thyroidectomy

An enhanced treatment effect can be expected from a higher serum thyroglobulin level after radioactive iodine therapy

Acknowledgements to reviewers

Phase I/IIa PET imaging study with 89zirconium labeled anti-PSMA minibody for urological malignancies